Clinical presentation of inhalational anthrax following bioterrorism exposure: report of 2 surviving patients.
about
New target for inhibition of bacterial RNA polymerase: 'switch region'Does Bacillus anthracis Lethal Toxin Directly Depress Myocardial Function? A Review of Clinical Cases and Preclinical StudiesIn vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunityAntimicrobial Treatment for Systemic Anthrax: Analysis of Cases from 1945 to 2014 Identified Through a Systematic Literature ReviewSyndromic surveillance and bioterrorism-related epidemicsAnthrax toxins induce shock in rats by depressed cardiac ventricular functionWhole Genome-Sequencing and Phylogenetic Analysis of a Historical Collection of Bacillus anthracis Strains from Danish CattleA conceptual framework for evaluating information technologies and decision support systems for bioterrorism preparedness and response.Human antibodies against spores of the genus Bacillus: a model study for detection of and protection against anthrax and the bioterrorist threat.Inter-alpha-inhibitor proteins are endogenous furin inhibitors and provide protection against experimental anthrax intoxication.Endemic infectious diseases of Afghanistan.Microevolution during an Anthrax outbreak leading to clonal heterogeneity and penicillin resistanceIn silico analysis suggests interaction between Ebola virus and the extracellular matrixBacillus anthracis lethal toxin induces TNF-alpha-independent hypoxia-mediated toxicity in miceBacillus anthracis lethal toxin alters regulation of visceral sympathetic nerve dischargeMolecular epidemiologic investigation of an anthrax outbreak among heroin users, Europe.Inhalational anthrax: radiologic and pathologic findings in two cases.Contribution of toxins to the pathogenesis of inhalational anthrax.The EMILIN/Multimerin family.Unusual bacterial infections and the pleura.The cost-effectiveness of strategies to reduce mortality from an intentional release of aerosolized anthrax spores.Characterization of AmiBA2446, a novel bacteriolytic enzyme active against Bacillus speciesGenetic polymorphisms and susceptibility to lung diseaseLethality during continuous anthrax lethal toxin infusion is associated with circulatory shock but not inflammatory cytokine or nitric oxide release in rats.Hawaii Physician and Nurse Bioterrorism Preparedness Survey
P2860
Q24634933-69E3595D-A705-4547-806C-F6BBFA3CDC6EQ26772000-C5DC1C39-7F01-4D40-9208-3E67D018C2CCQ28383065-AC5B447C-FF36-4667-AD97-D2346EECCE2EQ28383825-741E3E58-955D-4414-919B-6E662D1EDBC1Q28386064-79AEC162-8424-4D95-A9AB-ACC8B9E00EFCQ28469210-FE5B0C6B-E9E6-4C68-86B9-8B0ADEF37168Q28547621-54ABCEE5-A8CE-49A8-AE79-DCE9AFC92D0FQ30233274-1E5C8F94-23B9-43AF-847F-3DB2CE6BD313Q30701353-6ECE7785-60CC-4322-B8F2-70373A510AEFQ33946836-CA9C720C-6515-4EE6-A801-2F02D671DC0DQ34645383-2C25FAFC-A6D6-49DF-BDCA-A4B0F0A8FE70Q35097748-E2401367-A0FE-42BE-AF38-BD64A6554E01Q35099536-8340DCB3-8C28-420D-A287-25623D31FD06Q35679008-16EB4273-639A-432E-8A18-8CDF04A194EAQ35850562-3A9A0B20-A9D5-4A02-8C91-DADE90B27EA2Q36148002-F0D30026-190B-4379-B267-E1A123FDA122Q36662551-F8301575-C458-4540-A524-0AB19B45CE48Q36708397-EE489052-4CE1-420E-8275-364BE62F13CBQ38008348-DF69EAF9-6AEE-4268-993A-2F2BC093C2D4Q40274483-9864E409-50E3-49A1-8D27-CBF11B8D828DQ40344627-3342E885-D236-40FE-8536-A8C3481D5484Q41901019-E2FA2D58-FED4-4C76-A570-6B8759A8FBB5Q42414071-735EDEA3-28B9-4D5F-8F79-3344B3CE338CQ44364250-57A625FA-C461-4902-838A-74BE54CA008EQ57632860-891507A5-CEC7-400B-A1CC-AA8B8AE3DD76
P2860
Clinical presentation of inhalational anthrax following bioterrorism exposure: report of 2 surviving patients.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Clinical presentation of inhal ...... eport of 2 surviving patients.
@en
type
label
Clinical presentation of inhal ...... eport of 2 surviving patients.
@en
prefLabel
Clinical presentation of inhal ...... eport of 2 surviving patients.
@en
P2093
P356
P1476
Clinical presentation of inhal ...... eport of 2 surviving patients.
@en
P2093
D Hanfling
E L Berman
G Druckenbrod
J Rosenthal
P304
P356
10.1001/JAMA.286.20.2549
P407
P577
2001-11-01T00:00:00Z